Abstract:Background Treatment of pain and inflammation form the mainstay of osteoarthritis (OA) management. Non-steroidal anti-inflammatory drugs (NSAIDs), due to their inflammation-blocking mechanism, are a highly effective class of drugs for chronic pain and inflammation in OA. However, this comes at a cost of increased risk for multiple adverse effects, including gastrointestinal bleeding, cardiovascular side effects, and NSAID-induced nephrotoxicity. To minimize the potential risk of an adverse event, numerous regulatory bodies and medical societies recommend using the lowest effective NSAID dose for the shortest time necessary. One potential strategy to achieve this is the use of disease-modifying osteoarthritis drugs (DMOADs) containing anti-inflammatory and analgesic properties instead of NSAIDs for the management of OA. This study focuses on the efficacy of Clagen™ [Aflapin (Boswellia serrata extract) + native type 2 collagen + Mobilee (hyaluronic acid (60-70%), polysaccharides (>10%), and collagen (>5%)) + CurQlife (Curcumin)] for the symptomatic improvement in OA patients as well as if this combination is effective in the long-term management of OA instead of NSAIDs. Methodology In this retrospective observational study, a total of 300 patients were screened, of whom 100 OA patients who fulfilled the criteria and agreed to be part of the study were enrolled. The data were analyzed to evaluate the efficacy of the nutraceutical formulation Clagen™ in patients with OA of the knee. From the baseline to two months, primary outcomes of improvement in the Visual Analog Scale (VAS) score, range of motion, and Knee Injury and Osteoarthritis Outcome Score (KOOS) were measured at monthly follow-up. Statistical analyses were performed according to the results obtained from the parameters. The tests were performed at a 5% significance level (p <0.05). The qualitative characteristics were described using absolute and relative frequencies, and the quantitative measures were described as summary measures (mean, standard deviation). Results Of the 100 patients enrolled in the study, 99 (64 males and 35 females) completed the study. The mean age of the patients was 50.6 ± 13.9 years, and the mean body mass index was 24.5 ± 3.5 kg/m2. The statistical analysis of the outcomes from the baseline to the two-month follow-up was analyzed using paired t-test. The difference in the mean of VAS pain score at baseline and two months was 3.3 ± 1.8 [t (97) = 18.2; p < 0.05], which showed a significant reduction in pain at two months. Moreover, the difference in the mean of the goniometer value of 7.3 ± 7.3 [t (98) = -10.0, p < 0.05] indicated statistically significant improvements in the range of motion. It was also observed that Clagen™ significantly improved the composite KOOS score by 10.8% at the end of two months. Similarly, KOOS scores for Symptoms, Function, and Quality of Life showed improvements of 9.6%, 9.8%, and 7.8%, respectively, and were statistically significant (p < 0.05). Conclusions Clagen™ exerted positive adjuvant effects in the management of OA. The combination not only improved the symptoms and quality of life but, in the light of future perspective, NSAIDs can be withdrawn in OA patients, considering their long-term negative effects. To validate these findings further long-term studies with a comparison arm of NSAIDs are needed.

A cross-sectional survey of Indian orthopaedicians to understand the place in therapy for the latest soft gel formulation of etoricoxib

Novel Formulation Approaches used for the Management of Osteoarthritis: A Recent Review

Quality by design-based development and in vitro evaluation of dual release tablet of etoricoxib and thiocolchicoside: A novel chronotherapeutic approach for arthritis pain management

Etodolac utility in osteoarthritis: drug delivery challenges, topical nanotherapeutic strategies and potential synergies

DESIGN, FORMULATION, AND IN-VITRO EVALUATION OF IMMEDIATE RELEASE TABLET OF ETORICOXIB USING QUALITY BY DESIGN (QbD) APPROACH

Utilization of etoricoxib in dental patients in the Nordic countries: a population-based register study

Preference of Orthopedic Practitioners Toward the Use of Topical Medicine for Musculoskeletal Pain Management in China: A National Survey

Etoricoxib Versus Indometacin in the Treatment of Chinese Patients with Acute Gouty Arthritis: A Randomized Double-Blind Trial

EFFICACY, SAFETY, AND COST-EFFECTIVE ANALYSIS OF LOW-DOSE ETORICOXIB AND ADD-ON PARACETAMOL VERSUS THERAPEUTIC DOSE ETORICOXIB FOR PAIN IN PATIENTS AFTER TOOTH EXTRACTION: A RANDOMIZED INTERVENTIONAL DOUBLE-BLIND STUDY

The clinical study of etoricoxib in the treatment of Chinese patients with osteoarthritis

Ankle osteoarthritis: an online survey of current treatment practices of UK-based podiatrists and physiotherapists

Designing a clinical trial of non-steroidal anti-inflammatory drugs for cancer pain: a survey of UK palliative care physicians

Clinical effectiveness and tolerability of Celery seed and Boswellia serrata extract in osteoarthritis

A Retrospective Observational Study Evaluating the Synergistic Effect of a Novel Combination of Alfapin + Native Type 2 Collagen + Mobilee (Hyaluronic Acid) + CurQlife (Curcumin) Nutraceuticals in the Symptomatic Improvement of Knee Osteoarthritis

Real-world evidence evaluation on consumer experience and prescription journey of diclofenac gel in Sweden

Ionic liquid-based Ionogel: A novel strategy to improve dermal delivery and in vivo efficacy of etodolac in rheumatoid arthritis management

A Cross-Sectional Study on Patient Preferences for Selecting Surgeons for Joint Replacement Surgery in India

Nonsteroidal anti-inflammatory drugs for analgesia in intensive care units: a survey of Canadian critical care physicians

Current status of top 10 nutraceuticals used for Knee Osteoarthritis in India

Follicular mediated etodolac phosalosomal gel for contact dermatitis alleviation, insights from optimization to in-vivo appraisal

Clinical Evaluation of Maharasnadi Kvatha, Trayodashanga Guggulu, and Brihatsaindhavadya Taila in the management of knee osteoarthritis (Janugata Sandhivata): An open-label single-arm clinical study